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Purpose: Low-dose theophylline has anti-inflammatory effects. The aim of this 
study was to evaluate the effects of adding theophylline compared with increasing 
the dose of inhaled corticosteroid (ICS) on symptomatic asthma. Materials and 
Methods: The associated literature was acquired through deliberate searching and 
selected based on the established inclusion criteria for publications. The extracted 
data were further analyzed by a meta-analysis. Results: Four randomized, con-
trolled, parallel studies were selected. Addition of theophylline produced a greater 
increase of forced expiratory volume in one second as %predicted (FEV1pred) by 
2.49% [95% confidence interval (CI) 1.99-3.00; z = 9.70; p < 0.001], compared 
with increasing the dose of ICS. There was no difference between the two treat-
ments in terms of peak expiratory flow (PEF). Conclusion: Addition of theophyl-
line to ICS has similar therapeutic effects on improving lung function as increasing 
the dose of ICS in the treatment of symptomatic asthma.
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INTRODUCTION
Asthma is a chronic inflammatory disorder of the airway induced by a variety of 
inflammatory cells. Anti-inflammatory therapy is the cornerstone of asthma thera-
py, and corticosteroids are the most efficacious anti-inflammatory drugs for asth-
ma. Inhaled corticosteroid (ICS) has become a mainstay of asthma therapy. How-
ever, in many patients, asthma is not well controlled despite use of ICS. Global 
Initiative for Aathma (GINA) asthma guidelines1 recommend addition of long-act-
ing β2-agonist (LABA) or increasing the dose of ICS in patients whose asthma is 
not adequately controlled by low dose ICS, with addition of LABA being the first 
choice (Fig. 1). A meta-analysis conducted by Shrewsbury, et al.2 showed that ad-
dition of salmeterol to ICS produced better lung function, better control of symp-
toms, less need for rescue medication and fewer exacerbations than increasing the 
dose of ICS. However, the safety of LABA has been questioned. Recent studies 
suggest that use of LABA increases the risk of serious asthma-related events and Add Theophylline vs. Increase Inhaled Steroids
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tional Knowledge Infrastructure (CNKI, 1994-April 2010) 
databases using the following keyword terms: theophylline 
AND asthma AND steroid or corticosteroid. Trials were not 
excluded on the basis of language. Reference lists were 
searched for additional articles.
Titles, abstracts, and citations were independently re-
viewed by two reviewers to assess their potential relevance 
for full review. From the full text, both reviewers indepen-
dently assessed studies and procured the most relevant stud-
ies for inclusion based on our criteria. The following criteria 
were used for the literature selection for further meta-analy-
sis: 1) The papers should be randomized, controlled, parallel 
trials; 2) Direct comparison between adding theophylline to 
ICS and increasing the current ICS dosage in adults with 
asthma; 3) Despite treatment with ICS, patients had asthmat-
ic symptoms before the study or during the run-in period; 4) 
Data collection methods and analysis should be statistically 
acceptable. Accordingly, the following exclusion criteria 
were also used: 1) The design and definition of the trials were 
obviously different from those of selected papers; 2) Re-
views and repeated literatures were also excluded; 3) Not of-
fering the source of cases and controls and other essential in-
formation. We reviewed all papers in accordance with the 
criteria defined above for further analysis.
Data extraction and validity assessment
Data were extracted into contingency tables and entered into 
asthma mortality, despite the protective effect of ICS.3-5 
However, this opinion remains controversial. Other studies 
have shown that LABA therapy was not associated with an 
increased risk of severe asthma exacerbation and asthma-
related death.6,7 Addition of LABA and increasing the dose 
of ICS may also be expensive for patients, especially in de-
veloping countries. 
Many studies indicate that low-dose theophylline has an-
ti-infammatory effects and it can reduce eosinophilic in-
flammation. As shown by two withdrawal studies, low-dose 
theophylline provided further improvement of asthma con-
trol in patients already treated with ICS.8,9 Several studies 
showed that addition of theophylline to a low or moderate 
dose of ICS and increasing the dose had similar therapeutic 
effects in terms of improving lung function and asthmatic 
symptoms, and reducing the need for rescue medication.10-13 
The aim of this meta-analysis was to pool data from ran-
domized, controlled, parallel trials to examine the effects of 
addition of theophylline to ICS compared with increasing 
the dose of ICS in treating symptomatic asthmatic patients.
MATERIALS AND METHODS
Search strategy and selection criteria
We performed a comprehensive search of the PubMed (1966- 
April 2010), EMBASE (1974-April 2010) and China Na-
Fig. 1.  GINA asthma guidelines: management approach based on control for children > 5 years of age, adolescents and adults. The best-documented treat-
ment for controlling asthma is ICS. Low-dose ICS is recommended as the initial controller treatment at step 2, and low-dose ICS plus LABA is recommended 
at step 3. GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; LABA, long acting β2-agonist.
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were carried out in an attempt to explain the findings. The 
subgroup analyses were classified on duration of treatment. 
Sensitivity analysis was conducted on a statistical method 
of analysis (random vs fixed effects model). Meta-analysis 
was performed using Review Manager 4.2 (Cochrane Col-
laboration, Oxford, UK).
RESULTS
Literature search and meta-analysis databases
The flowchart of reviews shows the detailed selection pro-
cess (Fig. 2). A total of 14 randomized controlled trials 
(RCT) reporting a comparison of addition of theophylline 
to ICS versus increasing the dose of ICS were identified, of 
which four studies were selected. Using the methods of 
Jadad, et al.14 three studies were found to have a Jadad 
score of 3-4, and one study reported by Wang, et al.13 had a 
Jadad score of 2. We established a database according to 
the extracted information from each paper.
   
Study characteristics and design
The inclusion criteria and study characteristics are given in 
Tables 1 and 2. All study designs were randomized, con-
trolled and parallel groups, and three were double blind. 
The patients in all of the studies showed symptoms before 
randomized to treatment. 
   
Primary outcomes
Spirometric testing: All trials examined forced expiratory 
volume in one second (FEV1) using spirometry, and three 
trials reported percentage change in FEV1pred (Fig. 3). Ad-
a database. Extraction was performed by two independent re-
viewers. When the results were presented only in graphs, 
these were digitized and then converted to numbers (Digi-
tizeIt, version 1.5.7; DigitizeIt; Kŏln, Germany). In addition, 
we attempted to contact the investigators of the included 
studies to obtain further information for data extraction. Dis-
crepancies were resolved by consensus. Primary study au-
thors were requested to confirm data extraction and provide 
additional clarification or information for the review. The 
methodological quality of each trial was evaluated using the 
5-point scale (0 = worst and 5 = best) described by Jadad, et 
al.14 This instrument assesses the adequacy of randomization, 
blinding, and the handling of withdrawals and drop outs.
Data analysis
For forced expiratory volume in one second as %predicted 
(FEV1pred), peak expiratory flow (PEF, recorded by patients 
twice daily, morning and evening, on diary cards), the mea-
sure of effect size is the difference in mean between baseline 
results and post-treatment results for both groups. We sub-
tracted the results of increasing the ICS dose from the re-
sults of adding theophylline to obtain the net effect for all 
above measures. The net effects of each analysis were pooled 
using a random effect model or fixed-effect model for con-
tinuous outcomes, and a 95% confidence interval (CI) was 
calculated where appropriate. With pooled effects, hetero-
geneity was tested using the Chi-square-based Q statistic 
and measured additionally with the I2 test; I2 values of 25%, 
50%, and 75% represent low, moderate, and high heteroge-
neity, respectively. Otherwise, a p value of less than 0.10 for 
Chi-square value using a two tailed test was considered sig-
nificant. When heterogeneity was found, subgroup analyses 
Potentially relevant literatures identified from search strategy (n = 35)
Excluded if no comparison between adding theophylline to ICS and increasing dose of ICS (n = 21)
Reporting comparison between adding theophylline to ICS and increasing dose of ICS (n = 14)
Excluded if not in adults with asthma (n = 3)
Reporting comparison between adding theophylline to ICS and increasing dose of ICS in adults with asthma (n = 11)
Excluded if no information of prior use of ICS or asthmatic symptom before randomization (n = 7)
Included studies that fulfill inclusion criteria in meta-analysis (n = 4)
Fig. 2.  The flowchart of the study selection process. ICS, inhaled corticosteroid.Add Theophylline vs. Increase Inhaled Steroids
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dition of theophylline produced a significantly greater in-
crease by 2.49% [weighted means difference (WMD) = 
2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than in-
creasing the dose of ICS in FEV1pred. There was no statis-
tical heterogeneity between the trials (χ2 = 2.90; df = 2; p = 
0.23; I2 = 31.1%). 
Home PEF: All trials reported mean morning and eve-
ning PEF. There was no difference between treatments in 
terms of morning (p = 0.77)(Fig. 4) or evening (p = 0.20) 
PEF (Fig. 5). Significant interstudy heterogeneity was 
found in morning (χ2 = 71.30; df = 3; p < 0.00001; I2 = 
95.8%) and evening (χ2 = 26.10; df = 3; p < 0.00001; I2 = 
88.5%) PEF. Using subgroup analysis based on treatment 
duration, we found that the increases in PEF with addition 
of theophylline were higher, by 11.20 liter/min (95% CI 
9.14-13.25) in the morning and by 9.85 liter/min (95% CI 
7.55-12.14) in the evening, than with increasing the dose of 
ICS for the strata of six-week duration. For the strata of du-
ration longer than six weeks, evening PEF showed no dif-
ference, but the increase in morning PEF was in favor of in-
creasing the dose of ICS by 7.61 liter/min (95% CI 3.72-
11.50). 
Sensitivity analysis
To evaluate the sensitivity of meta-analysis, we calculated 
the random effect model for FEV1pred. The random effect 
Table 1. Inclusion Criteria from Individual Studies
Reference
Age 
(yrs)
ICS (µg/day)
FEV1/PEF 
reversibility (%)
Lung function as 
% predicted
Symptoms Oral steroid use  Exacerbation
Evans, et al.
10 18 - 67 800 - 1,000 ≥ 15 FEV1 ≥ 50 Yes Not in past 3 weeks Not in past 3 weeks
Ukena, et al.
11 18 - 70 400  ≥ 15 FEV1 50 - 80 Yes None
Lim, et al.
12 18 - 65 400 ≥ 15 PEF ≥ 50 Yes None Not in past 6 weeks
Wang, et al.
13 18 - 70  ≤ 1,000 ≥ 15 Yes Not in past 4 weeks
The dose of ICS is the dose of inhaled beclometasone dipropionate (BDP) or equivalent dose of other ICS. Patients were asked to record presence (yes) or 
absence (no) of symptoms.
ICS, inhaled corticosteroid; FEV1, forced expiratory volume in one second; PEF, peak expiratory flow. 
Table 2.  Characteristics and Study Design of Trials Included
Reference 
Study 
design 
Patients 
(n)
Men 
(%)
Dropouts 
(%)
Duration 
(weeks)
ICS
Baseline  
dose (µg/day)
Comparison 
dose (µg/day)
Theophylline 
dose    
Theophylline plasma 
level (µg/mL)
Evans, et al.
10 RCT(DB)   62 40.3       6.0 12 BUD 400 µg bid 800 µg bid 0.25 g / 0.375 g bid 2.5 - 17.1 (median: 8.7)
Ukena, et al.
11 RCT(DB) 133 56.4 30.0   6  BDP 200 µg bid 400 µg bid 0.25 g / 0.375 g bid   10.1 ± 4.2
Lim, et al.
12 RCT(DB)   85 48.5 15.8 26 BDP 200 µg bid 500 µg bid 0.2 g bid None
Wang, et al.
13 RCT   38 39.5   7.3   6 BDP 250 µg bid 500 µg bid 0.2 g bid None
ICS, inhaled corticosteroid; RCT, randomized controlled trial; DB, double blind; BDP, beclometasone dipropionate; BUD, budesonide; bid, twice daily.
Fig. 3. Pooled WMD for the improvement of FEV1pred of eligible studies comparing the addition of theophylline (treatment) with increasing the dose of ICS 
(control). FEV1pred, forced expiratory volume in one second as %predicted; Theo, theophylline; ICS, inhaled corticosteroid; WMD, weighted mean differ-
ence; CI, confidence interval.
Review: Addition of theophylline versus increasing the dose of inhaled steroid
Comparison: 01 addition of theophylline yersus increasing the dose of inhaled steroid
Outcome: 01 The change of FEV1pred
Study or sub-
category n Addition of Theo 
mean (SD) n Increasing ICS 
mean (SD)
WMD (fixed) 
95% CI Weight (%) WMD (fixed) 
95% CI Year
Evens, et al.
10 31   4.90 (1.70)   31   2.00 (1.20)   47.28 2.90 (2.17, 3.63)
Ukena, et al.
11 69 10.10 (2.10)   64   8.00 (2.00)   52.24 2.10 (1.40, 2.80)
Wang, et al.
13 19   15.20 (13.10)   19 10.10 (9.50)     0.48     5.10 (-2.18, 12.38)
Total (95% CI) 119 114 100.00 2.49 (1.99, 3.00)
Test for heterogeneity: Chi
2 = 2.90, df = 2 (p = 0.23), I
2 = 31.1%
Test for overall effect: z = 9.70 (p < 0.00001)
     -10           -5            0            5            10
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Fig. 4. Pooled WMD for improvement of morning PEF in eligible studies comparing addition of theophylline (treatment) with increasing the dose of ICS (con-
trol). PEF, peak expiratory flow; Theo, theophylline; ICS, inhaled corticosteroid; WMD, weighted mean difference; CI, confidence interval.
Fig. 5. Pooled WMD for the improvement of evening PEF of eligible studies comparing addition of theophylline (treatment) with increasing the dose of ICS 
(control). PEF, peak expiratory flow; Theo, theophylline; ICS, inhaled corticosteroid; WMD, weighted mean difference; CI, confidence interval.
Review: Addition of theophylline versus increasing the dose of inhaled steroid
Comparison: 01 addition of theophylline versus increasing the dose of inhaled steroid
Outcome: 03 The change of evening PEF
Study or sub-cate-
gory n Addition of Theo 
mean (SD) n Increasing ICS 
mean (SD)
WMD (random) 
95% CI Weight (%) WMD (random) 
95% CI Year
01 Duration of 6 weeks
    Ukena, et al.
11 69 24.34 (9.83) 64 14.50 (5.62) 38.66 9.84 (7.54, 12.14)
    Wang, et al.
13 19   30.80 (34.30) 19 19.90 (54.30) 8.51     10.90 (-17.98, 39.78)
Subtotal (95% CI) 88 83 47.17 9.85 (7.55, 12.14)
Test for heterogeneity: Chi
2 = 0.01, df = 1 (p = 0.94), I
2 = 0%
Test for overall effect: z = 8.40 (p < 0.00001)
02 Duration of more then 6 weeks
    Evans, et al.
10 31 11.00 (8.10) 31 13.00 (7.90) 36.99   -2.00 (-5.98, 1.98)
    Lim, et al.
12 38   22.50 (42.45) 47 8.30 (44.23) 15.84     14.20 (-4.29, 32.69)
Subtotal (95% CI) 69 78 52.83   9.48 (-11.54, 18.50)
Test for heterogeneity: Chi
2 = 2.82, df = 1 (p = 0.92), I
2 = 64.5%
Test for overall effect: z = 0.45 (p = 0.65)
Total (95% CI) 157 161 100.00     6.24 (-3.27, 15.75)
Test for heterogeneity: Chi
2 = 26.10, df = 3 (p < 0.00001), I
2 = 88.5%
Test for overall effect: z = 1.29 (p = 0.20)
      -100        -50           0            50         100
  Favours treatment             Favours control
Review: Addition of theophylline versus increasing the dose of inhaled steroid
Comparison: 01 addition of theophylline versus increasing the dose of inhaled steroid
Outcome: 02 The change of morning PEF
Study or sub-cate-
gory n Addition of Theo 
mean (SD) n Increasing ICS 
mean (SD)
WMD (random) 
95% CI Weight (%) WMD (random) 
95% CI Year
01 Duration of 6 weeks
    Ukena, et al.
11 69 33.23 (6.77) 64 22.01 (5.29) 33.64 11.22 (9.16, 13.28)
    Wang, et al.
13 19   31.10 (44.20) 19 26.10 (59.90) 12.38      5.00 (-28.47, 38.47)
Subtotal (95% CI) 88 83 46.02 11.20 (9.14, 13.25)
Test for heterogeneity: Chi
2 = 0.13, df = 1 (p = 0.72), I
2 = 0%
Test for overall effect: z = 10.69 (p < 0.00001)
02 Duration of more then 6 weeks
    Evans, et al.
10 31 14.00 (8.50) 31 22.00 (7.40) 33.05   -8.00 (-11.97, -4.03)
    Lim, et al.
12 38   21.80 (46.25) 47 19.50 (47.29) 20.93     2.30 (-17.68, 22.28)
Subtotal (95% CI) 69 78 53.98   -7.61 (-11.50, -3.72)
Test for heterogeneity: Chi
2 = 0.96, df = 1 (p = 0.32), I
2 = 0%
Test for overall effect: z = 3.83 (p < 0.0001)
Total (95% CI) 157 161 100.00     2.23 (-12.56, 17.02)
Test for heterogeneity: Chi
2 = 71.30, df = 3 (p < 0.00001), I
2 = 95.8%
Test for overall effect: z = 0.30 (p < 0.77)
      -100        -50           0            50         100
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has attracted greater attention because of its anti-inflammato-
ry effects. In clinical trials, theophylline decreased eosinophil 
count and eosinophil cationic protein in sputum, blood and 
bronchoalveolar lavage15-17 and suppressed the late asthmat-
ic response to nighttime antigen challenge.18 Theophylline 
also suppressed the expression of pro-inflammatory cyto-
kines19,20 and restrained degranulation and release of in-
flammatory mediators.21-23 Recent studies show that theoph-
ylline has anti-inflammatory effects in the treatment of 
chronic obstructive pulmonary disease.24,25 
In this study, our results demonstrated that, compared with 
increasing the dose of ICS, addition of theophylline led to a 
greater improvement of FEV1pred by 2.49%. There was no 
statistical heterogeneity, and the sensitivity analysis showed 
that the random and fixed effects models for FEV1pred had 
similar results. We also found no difference in PEF between 
the two treatments. However, statistically significant het-
erogeneity was found in the analysis of PEF. Subgroup 
analysis showed that addition of theophylline led to more 
improvement of PEF than increasing the dose of ICS for 
the strata of six-week treatment duration, but not for treat-
ment duration of more than six weeks. Furthermore, the in-
crease of morning PEF was in favor of increasing the dose 
of ICS for the strata of duration of more than 6 weeks. 
These results suggested that the addition of theophylline 
yielded a greater increase in PEF than increasing the dose 
of ICS, but only in short duration treatment. This result may 
be attributed to the bronchodilator activity of theophylline. 
Increasing the dose of ICS exerted an anti-inflammatory ef-
fect, resulting in similar or further improvement of PEF 
than the addition of theophylline in treatment of long dura-
model of FEV1pred showed a pooled WMD of 2.51 (95% 
CI 1.82-3.20)(Fig. 6), similar to the result (WMD = 2.49; 
95% CI 1.99-3.00) obtained from the fixed-effect model. 
Secondary outcomes
Rescue medication and symptom scores: All four trials re-
vealed improvement of symptom scores and need for res-
cue medication in both groups, and there was no significant 
difference between the two treatments.
Plasma cortisol level: Two trials measured plasma corti-
sol level. Evans, et al.10 reported that the reduction of plas-
ma cortisol level was observed only in the group given an 
increased dose of ICS after 12-week treatment. Wang, et 
al.13 found there was no significant reduction in plasma cor-
tisol in both treatments.
Exacerbations: Two trials examined exacerbation rates due 
to asthma, and their results showed there were no statistical 
differences in exacerbation rates between the groups.10,12 Fu-
thermore, Lim, et al.12 indicated that eight patients (5.2%) 
with an increase in ICS dose and three patients (1.9%) with 
addition of theophylline reported exacerbations, and that 
there was a trend towards fewer exacerbations with the ad-
dition of theophylline.
c a DISCUSSION
In past, theophylline has been applied worldwide for the 
treatment of asthma and is usually prescribed as bronchodila-
tor therapy due to its inhibition of phosphodiesterase activi-
ties in airway smooth muscle. In recent years, theophylline 
Fig. 6. Sensitivity analysis: Pooled WMD for improvement of FEV1pred in eligible studies comparing addition of theophylline (treatment) with increasing the 
dose of ICS (control) using the random effects model. FEV1pred, forced expiratory volume in one second as %predicted; Theo, theophylline; ICS, inhaled cor-
ticosteroid; WMD, weighted mean difference; CI, confidence interval.
Review: Addition of theophylline versus increasing the dose of inhaled steroid
Comparison: 01 addition of theophylline versus increasing the dose of inhaled steroid
Outcome: 01 The change of FEV1pred
Study or sub-
category n Addition of Theo 
mean (SD) n Increasing ICS 
mean (SD)
WMD (random) 
95% CI Weight (%) WMD (random) 
95% CI Year
Evens, et al.
10 31   4.90 (1.70)   31   2.00 (1.20)   48.24 2.90 (2.17, 3.63)
Ukena, et al.
11 69 10.10 (2.10)   64   8.00 (2.00)   50.86 2.10 (1.40, 2.80)
Wang, et al.
13 19   15.20 (13.10)   19 10.10 (9.50)     0.89     5.10 (-2.18, 12.38)
Total (95% CI) 119 114 100.00 2.51 (1.82, 3.20)
Test for heterogeneity: Chi
2 = 2.90, df = 2 (p = 0.23), I
2 = 31.1%
Test for overall effect: z = 7.12 (p < 0.00001)
     -10           -5            0            5            10
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criteria were missed. There was a possibility of publication 
bias in this meta-analysis. Fourth, we did not make a meta-
analysis of adverse events. The evaluation of adverse effects 
was difficult to pool because there was no standardized re-
porting. As we know, theophylline has side effects that oc-
cur commonly, such as nausea, vomiting, and cardiac ar-
rhythmias. However, low-dose theophylline, used in the 
four studies included, should cause fewer severe adverse 
events. Fifth, further observation should be required be-
cause of the small sample sizes and the small number of in-
cluded studies. Despite these limitations, we believe that 
these pooled results provide valuable information.
In conclusion, adding theophylline to ICS has similar 
therapeutic effects in improving lung function to increasing 
the dose of ICS in the treatment of symptomatic asthmatic 
patients. Theophylline is also cheaper than either ICS or 
LABA. Addition of theophylline may be an appropriate 
treatment choice for symptomatic asthma patients currently 
taking ICS, especially in developing countries. More high 
quality, multicenter, controlled, double-blind trials are re-
quired due to our studies’ limitations. 
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